Insights into the workings of PD-1 reveal how treatments that restrict its action can potentially be strengthened to improve their anticancer effect, a new study shows.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
